Glenmark Pharmaceuticals announced that SES ESG Research Private Limited assigned it an ESG rating of “71.1” for the fiscal year 2025. The rating was assigned on January 4, 2026, based on publicly available information. Glenmark clarifies it did not engage SES ESG for this rating. The company has recorded the assessment.
ESG Rating Announcement
Glenmark Pharmaceuticals has received an ESG rating from SES ESG Research Private Limited. An email on January 04, 2026, confirmed the company’s ESG rating of “71.1” for Fiscal Year 2025.
Independent Assessment
The company clarified it has not engaged SES ESG for ESG rating purposes. SES ESG independently assigned the rating based on publicly accessible information for FY 2025.
Source: BSE
